KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Notes Payables (2018 - 2024)

Amneal Pharmaceuticals has reported Notes Payables over the past 5 years, most recently at $41.9 million for Q1 2024.

  • Quarterly results put Notes Payables at $41.9 million for Q1 2024, changed N/A from a year ago — trailing twelve months through Mar 2024 was $41.9 million (changed N/A YoY), and the annual figure for FY2023 was $41.4 million, up 4.38%.
  • Notes Payables for Q1 2024 was $41.9 million at Amneal Pharmaceuticals, up from $41.4 million in the prior quarter.
  • Over the last five years, Notes Payables for AMRX hit a ceiling of $41.9 million in Q1 2024 and a floor of $1.0 million in Q1 2020.
  • Median Notes Payables over the past 4 years was $39.7 million (2022), compared with a mean of $23.2 million.
  • Peak annual rise in Notes Payables hit 4.38% in 2023, while the deepest fall reached 4.38% in 2023.
  • Amneal Pharmaceuticals' Notes Payables stood at $1.0 million in 2020, then surged by 3870.6% to $39.7 million in 2022, then rose by 4.38% to $41.4 million in 2023, then increased by 1.08% to $41.9 million in 2024.
  • The last three reported values for Notes Payables were $41.9 million (Q1 2024), $41.4 million (Q4 2023), and $41.0 million (Q3 2023) per Business Quant data.